Table 1. Clinical Characteristics.
| Group A (n = 51) | Group B (n = 60) | Group C (n = 57) | p Values | |
| Age(years) | 60±11 | 61±14 | 58±13 | 0.374 |
| Male Gender, % | 32(63) | 39(65) | 42(74) | 0.432 |
| Heart rate | 66±7 | 67±9 | 70±15 | 0.104 |
| Mean BP (mmHg) | 106±11 | 106±13 | 110±11 | 0.118 |
| Coronary artery disease, % | 29(57) | 40(67) | 51(90) | 0.001† ‡ |
| Killip III or IV, % | 5(10) | 14(23) | 15(26) | 0.078 |
| Hyperlipidemia, % | 18(35) | 23(38) | 29(51) | 0.211 |
| Diabetes mellitus, % | 22(43) | 29(48) | 23(40) | 0.677 |
| Hypertension, % | 27(53) | 30(50) | 24(42) | 0.500 |
| Medications | ||||
| Antiplatelet agents, % | 43(84) | 51(85) | 51(90) | 0.690 |
| ACEI or ARB, % | 25(49) | 32(53) | 26(46) | 0.704 |
| Beta blockers, % | 39(77) | 49(82) | 45(79) | 0.797 |
| Statin, % | 18(35) | 32(53) | 26(46) | 0.163 |
| Therapy | ||||
| Coronary revascularization, % | 26(51) | 34(57) | 33(58) | 0.746 |
†
Group A (LVEDP <16 mmHg) versus Group C (LVEDP> 30 mmHg), p<0.05 in post hoc analysis.
‡
Group B (LVEDP 16–30 mmHg) versus Group C, p<0.05 in post hoc analysis.
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure; LVEDP, left ventricular end-diastolic pressure; NYHA, New York Heart Association.